Non-cutaneous Melanoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2024-08-27
Clinical Trial Update: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery [Phase 3]
A Phase 3 trial comparing high-dose recombinant interferon alfa-2B or ipilimumab to pembrolizumab in patients with surgically removed stage …